Show simple item record

dc.contributor.authorBogers, Sophie Helen
dc.date.accessioned2018-07-24T17:01:37Z
dc.date.available2018-07-24T17:01:37Z
dc.date.issued2018-04-16
dc.identifier.urihttp://hdl.handle.net/10919/84309
dc.description.abstractBiological cell-based therapies for the treatment of joint disease in veterinary patients include autologous-conditioned serum, platelet-rich plasma, and expanded or nonexpanded mesenchymal stem cell products. This narrative review outlines the processing and known mechanism of action of these therapies and reviews current preclinical and clinical efficacy in joint disease in the context of the processing type and study design. The significance of variation for biological activity and consequently regulatory approval is also discussed. There is significant variation in study outcomes for canine and equine cell-based products derived from whole blood or stem cell sources such as adipose and bone marrow. Variation can be attributed to altering bio-composition due to factors including preparation technique and source. In addition, study design factors like selection of cases with early vs. late stage osteoarthritis (OA), or with intra-articular soft tissue injury, influence outcome variation. In this under-regulated field, variation raises concerns for product safety, consistency, and efficacy. Cell-based therapies used for OA meet the Food and Drug Administration’s (FDA’s) definition of a drug; however, researchers must consider their approach to veterinary cell-based research to meet future regulatory demands. This review explains the USA’s FDA guidelines as an example pathway for cellbased therapies to demonstrate safety, effectiveness, and manufacturing consistency. An understanding of the variation in production consistency, effectiveness, and regulatory concerns is essential for practitioners and researchers to determine what products are indicated for the treatment of joint disease and tactics to improve the quality of future research.
dc.format.mimetypeapplication/pdfen_US
dc.language.isoen_US
dc.publisherFrontiers
dc.rightsCreative Commons Attribution 4.0 International (CC BY 4.0)*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectmesenchymal stem cells
dc.subjectosteoarthritis
dc.subjectplatelet-rich plasma
dc.subjectautologous-conditioned serum
dc.subjectcell-based therapies
dc.subjectFood and Drug Administration regulation
dc.subjectautologous conditioned plasma
dc.titleCell-Based Therapies for Joint Disease in Veterinary Medicine: What We Have Learned and What We Need to Knowen_US
dc.typeArticle - Refereeden_US
dc.title.serialFrontiers in Veterinary Science
dc.identifier.doihttps://doi.org/10.3389/fvets.2018.00070
dc.identifier.volume5
dc.type.dcmitypeTexten_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Creative Commons Attribution 4.0 International (CC BY 4.0)
License: Creative Commons Attribution 4.0 International (CC BY 4.0)